CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsiesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1017 Guanfacine hydrochloride (SPD503) Wiki 1.00
drug236 Atomoxetine hydrochloride Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D006948 Hyperkinesis NIH 0.71
D001289 Attention Deficit Disorder with Hyperactivity NIH 0.50

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002487 Hyperkinetic movements HPO 0.71
HP:0007018 Attention deficit hyperactivity disorder HPO 0.50

There is one clinical trial.

Clinical Trials


1 Study of the Sars-Cov2 Neuroinvasiveness - COVID19

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

NCT04427254 COVID19 Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Primary Outcomes

Description: COVID-19 RT-PCR test

Measure: Percentage of patients with COVID-19 positive samples/biopsies

Time: At the time of the inclusion


No related HPO nodes (Using clinical trials)